Fewer than a tenth of people that would benefit from obesity jabs like Wegovy have access to them, states the World Health Organization as it issues its initial guidance on the medications.
With in excess of 1,000,000,000 individuals worldwide now obese, it is advocating for broader and more equitable availability to these injectable treatments.
According to projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.
"The latest guidelines acknowledges that obesity is a lifelong illness that can be managed with comprehensive and lifelong care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and logistical bottlenecks are key obstacles to broad availability to the jabs that can assist patients in reducing significant body mass, notes the body.
Skinny Jab Shortage
Even under the present most favorable outlook, the production of these medications could only cover about 100 million people – fewer than 10% of those who need them, according to the WHO.
The advice encourages nations and manufacturers to expand availability, through strategies including licensing agreements.
The intellectual property rights on the active ingredient – the core ingredient of the drug Wegovy – is due to expire in several nations in 2026.
The Way Weight-Loss Injections Function
The injections imitate a body's own hormone to reduce digestion speed, curb appetite and enhance satiety so people reduce food intake.
Individuals usually see weight reduction in the initial weeks of starting on the weekly injections.
Evidence indicates people may see weight return a year later of stopping the drug, when their typical hunger resume.
Being overweight or obese increases your risk for contracting medical conditions, including type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.
Obesity concerns individuals in every country and was associated with over three and a half million fatalities worldwide in 2024, per the WHO.
